Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: Potential for drug target

References

• Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9: 43–57
   PubMed Web of Science ®Google Scholar
• Gores GJ. Cholangiocarcinoma: Current concepts and insights. Hepatology 2003; 37: 961–9
   PubMed Web of Science ®Google Scholar
• Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806–13
   PubMed Web of Science ®Google Scholar
• Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353–7
   PubMed Web of Science ®Google Scholar
• Jackson R, Hunter T. Role of methionine in the initiation of haemoglobin synthesis. Nature 1970; 227(5259)672–6
   PubMedGoogle Scholar
• Arfin SM, Kendall RL, Hall L, Weaver LH, Stewart AE, Matthews BW, et al. Eukaryotic methionyl aminopeptidases: Two classes of cobalt-dependent enzymes. Proc Natl Acad Sci USA 1995; 92(17)7714–8
   PubMed Web of Science ®Google Scholar
• Li X, Chang YH. Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases. Proc Natl Acad Sci USA 1995; 92(26)12357–61
   PubMedGoogle Scholar
• Shusterman S, Maris JM. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett 2005; 228: 171–9
   PubMed Web of Science ®Google Scholar
• Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 1997; 94(12)6099–103
   PubMed Web of Science ®Google Scholar
• Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 1997; 4: 461–71
   PubMed Web of Science ®Google Scholar
• Castronovo V, Belotti D. TNP-470 (AGM-1470): Mechanisms of action and early clinical development. Eur J Cancer 1996; 32A: 2520–7
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind CH. TNM classification of malignant tumours5th ed. John Wiley & Sons, New York 1997
   Google Scholar
• Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudiswardi V, Puapairoj A, et al. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol 2005; 11: 3392–7
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107–12
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227(5259)680–5
   PubMed Web of Science ®Google Scholar
• Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76(9)4350–4
   PubMed Web of Science ®Google Scholar
• Fan TP. Angiosuppressive therapy for cancer. Trends Pharmacol Sci 1994; 15: 33–6
   PubMedGoogle Scholar
• Turk BE, Griffith EC, Wolf S, Biemann K, Chang YH, Liu JO. Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 1999; 6: 823–33
   PubMed Web of Science ®Google Scholar
• Liu S, Widom J, Kemp CW, Crews CM, Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 1998; 282(5392)1324–7
   PubMed Web of Science ®Google Scholar
• Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci USA 1998; 95(26)15183–8
   PubMed Web of Science ®Google Scholar
• Datta R, Choudhury P, Ghosh A, Datta B. A glycosylation site, 60SGTS63, of p67 is required for its ability to regulate the phosphorylation and activity of eukaryotic initiation factor 2alpha. Biochemistry 2003; 42: 5453–60
   PubMed Web of Science ®Google Scholar
• Bernier SG, Taghizadeh N, Thompson CD, Westlin WF, Hannig G. Methionine aminopeptidases type I and type II are essential to control cell proliferation. J Cell Biochem 2005; 95: 1191–203
   PubMedGoogle Scholar
• Sirica AE. Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy. Hepatology 2005; 41: 5–15
   PubMed Web of Science ®Google Scholar
• Suh KS, Roh HR, Koh YT, Lee KU, Park YH, Kim SW. Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology 2000; 31: 12–7
   PubMedGoogle Scholar
• Kanno T, Endo H, Takeuchi K, Morishita Y, Fukayama M, Mori S. High expression of methionine aminopeptidase type 2 in germinal center B cells and their neoplastic counterparts. Lab Invest 2002; 82: 893–901
   PubMedGoogle Scholar
• Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: Role of Bcl-2 expression and telomerase activity. Am J Pathol 2001; 159: 721–31
   PubMedGoogle Scholar
• Sheen IS, Jeng KS, Jeng WJ, Jeng CJ, Wang YC, Gu SL, et al. Fumagillin treatment of hepatocellular carcinoma in rats: An in vivo study of antiangiogenesis. World J Gastroenterol 2005; 11: 771–7
   PubMedGoogle Scholar
• Dummitt B, Micka WS, Chang YH. Yeast glutamine-fructose-6-phosphate aminotransferase (Gfa1) requires methionine aminopeptidase activity for proper function. J Biol Chem 2005; 280: 14356–60
   PubMedGoogle Scholar
• Covalt JC, Jr, Cao TB, Magdaroag JR, Gross LA, Jennings PA. Temperature, media, and point of induction affect the N-terminal processing of interleukin-1beta. Protein Expr Purif 2005; 41: 45–52
   PubMedGoogle Scholar
• Kusaka M, Sudo K, Fujita T, Marui S, Hoh F, Ingber D, et al. Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent. Biochem Biophys Res Commun 1991; 174: 1070–6
   PubMed Web of Science ®Google Scholar
• Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 2001; 7: 977–84
   PubMed Web of Science ®Google Scholar
• Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remide SC, Cooley TP, et al. Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998; 16: 1444–9
   PubMed Web of Science ®Google Scholar
• Kruger EA, Figg WD. TNP-470: An angiogenesis inhibitor in clinical development for cancer. Expert Opin Investig Drugs 2000; 9: 1383–96
   PubMed Web of Science ®Google Scholar
• Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997; 3: 1501–5
   PubMed Web of Science ®Google Scholar
• Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999; 17: 2541–5
   PubMed Web of Science ®Google Scholar
• Chun E, Han CK, Yoon JH, Sim TB, Kim YK, Lee KY. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer 2005; 114: 124–30
   PubMed Web of Science ®Google Scholar
• Wang AG, Yoon SY, Oh JH, Jeon YJ, Kim M, Kim JM, et al. Identification of intrahepatic cholangiocarcinoma related genes by comparison with normal liver tissues using expressed sequence tags. Biochem Biophys Res Commun 2006; 345: 1022–32
   PubMed Web of Science ®Google Scholar
• Obama K, Ura K, Li M, Katagiri T, Tsunoda T, Nomura A, et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 2005; 41: 1339–48
   PubMed Web of Science ®Google Scholar
• Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002; 36: 439–50
   PubMed Web of Science ®Google Scholar
• Berthiaume EP, Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004; 24: 127–37
   PubMed Web of Science ®Google Scholar
• Nakanuma Y, Harada K, Ishikawa A, Zen Y, Sasaki M. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003; 10: 265–81
   PubMedGoogle Scholar
• Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology 2004; 66: 167–79
   PubMed Web of Science ®Google Scholar